User login
Highlights in Early Breast Cancer From ESMO 2023
Developments in early breast cancer reported at the European Society for Medical Oncology (ESMO) 2023 Congress are discussed by Dr Lisa Carey of University of North Carolina, Chapel Hill.
Dr Carey begins with 5-year results from the KEYNOTE-522 study in patients with early triple-negative breast cancer in which the immune checkpoint inhibitor pembrolizumab was incorporated into combination therapy both pre- and postoperatively. The new findings were consistent with earlier results, showing that pembrolizumab improved pathologic complete response (pCR) and event-free survival.
Turning to human epidermal growth factor receptor 2–positive (HER2+) disease, Dr Carey discusses the PHERGain trial's use of a genomic assay to define risk and predict pCR. She suggests that such assays could lead to tailored therapy for HER2+ patients.
On estrogen receptor–positive (ER+)/HER2- disease, Dr Carey reports first on KEYNOTE-756, which examined the addition of pembrolizumab to combination therapy for high-risk patients in both the neoadjuvant and adjuvant settings. Pembrolizumab improved pCR compared with placebo.
Dr Carey closes by discussing another study in high-risk ER+/HER2- disease. Similar in design to KEYNOTE-756, CheckMate 7FL found that nivolumab added to combination therapy again augmented pCR results.
--
Lisa A. Carey, MD, Distinguished Professor or Breast Cancer Research, University of North Carolina Lineberger Comprehensive Cancer Center; Professor, Division of Medical Oncology, Bassnight North Carolina Cancer Hospital, Chapel Hill, North Carolina
Lisa A. Carey, MD, has disclosed no relevant financial relationships.
Developments in early breast cancer reported at the European Society for Medical Oncology (ESMO) 2023 Congress are discussed by Dr Lisa Carey of University of North Carolina, Chapel Hill.
Dr Carey begins with 5-year results from the KEYNOTE-522 study in patients with early triple-negative breast cancer in which the immune checkpoint inhibitor pembrolizumab was incorporated into combination therapy both pre- and postoperatively. The new findings were consistent with earlier results, showing that pembrolizumab improved pathologic complete response (pCR) and event-free survival.
Turning to human epidermal growth factor receptor 2–positive (HER2+) disease, Dr Carey discusses the PHERGain trial's use of a genomic assay to define risk and predict pCR. She suggests that such assays could lead to tailored therapy for HER2+ patients.
On estrogen receptor–positive (ER+)/HER2- disease, Dr Carey reports first on KEYNOTE-756, which examined the addition of pembrolizumab to combination therapy for high-risk patients in both the neoadjuvant and adjuvant settings. Pembrolizumab improved pCR compared with placebo.
Dr Carey closes by discussing another study in high-risk ER+/HER2- disease. Similar in design to KEYNOTE-756, CheckMate 7FL found that nivolumab added to combination therapy again augmented pCR results.
--
Lisa A. Carey, MD, Distinguished Professor or Breast Cancer Research, University of North Carolina Lineberger Comprehensive Cancer Center; Professor, Division of Medical Oncology, Bassnight North Carolina Cancer Hospital, Chapel Hill, North Carolina
Lisa A. Carey, MD, has disclosed no relevant financial relationships.
Developments in early breast cancer reported at the European Society for Medical Oncology (ESMO) 2023 Congress are discussed by Dr Lisa Carey of University of North Carolina, Chapel Hill.
Dr Carey begins with 5-year results from the KEYNOTE-522 study in patients with early triple-negative breast cancer in which the immune checkpoint inhibitor pembrolizumab was incorporated into combination therapy both pre- and postoperatively. The new findings were consistent with earlier results, showing that pembrolizumab improved pathologic complete response (pCR) and event-free survival.
Turning to human epidermal growth factor receptor 2–positive (HER2+) disease, Dr Carey discusses the PHERGain trial's use of a genomic assay to define risk and predict pCR. She suggests that such assays could lead to tailored therapy for HER2+ patients.
On estrogen receptor–positive (ER+)/HER2- disease, Dr Carey reports first on KEYNOTE-756, which examined the addition of pembrolizumab to combination therapy for high-risk patients in both the neoadjuvant and adjuvant settings. Pembrolizumab improved pCR compared with placebo.
Dr Carey closes by discussing another study in high-risk ER+/HER2- disease. Similar in design to KEYNOTE-756, CheckMate 7FL found that nivolumab added to combination therapy again augmented pCR results.
--
Lisa A. Carey, MD, Distinguished Professor or Breast Cancer Research, University of North Carolina Lineberger Comprehensive Cancer Center; Professor, Division of Medical Oncology, Bassnight North Carolina Cancer Hospital, Chapel Hill, North Carolina
Lisa A. Carey, MD, has disclosed no relevant financial relationships.
Highlights in Metastatic Breast Cancer From ASCO 2021
Dr. Lisa Carey, a breast cancer specialist from the University of North Carolina at Chapel Hill, looks at the latest data in metastatic breast cancer presented at the 2021 American Society of Clinical Oncology Annual Meeting.
First, Dr. Carey reviews an updated analysis from the PALOMA-3 trial of the CDK4/6 inhibitor palbociclib plus fulvestrant in women with HR+/HER2- advanced disease. This report showed that the observed survival benefit with the combination is maintained out to 6 years.
Next, she describes another updated survival analysis, this time from the MONALEESA-3 trial, which assessed fulvestrant plus another CDK4/6 inhibitor, ribociclib, in postmenopausal women with HR+/HER2- advanced disease. Again, the combination was associated with a survival benefit of almost 5 years, as well as a delay in subsequent chemotherapy.
Dr. Carey then reviews the Chinese sysucc-002 trial of endocrine therapy or chemotherapy added to trastuzumab in HR+/HER2+ disease. With noninferior outcomes and lower toxicity, trastuzumab plus endocrine therapy could become the preferred option and allow women to avoid chemotherapy.
She next turns to a subanalysis of the ASCENT trial, which examined sacituzumab govitecan in previously treated triple-negative disease. Even in the second-line metastatic setting, the drug showed a survival benefit.
Dr. Carey concludes by discussing a study that gathered patients’ views on treatment-related adverse effects, finding that over 90% would be willing to discuss alternative dosing options to improve their quality of life.
--
Jacobs Preyer Distinguished Professor, Breast Cancer Research, University of North Carolina at Chapel Hill; Deputy Director, Clinical Sciences, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Lisa A. Carey, MD, has disclosed the following relevant financial relationships:
Institution received research funding from: AbbVie; Immunomedics; NanoString Technologies; Novartis; Seattle Genetics; Syndax; Veracyte
Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme.
Other uncompensated relationships through institution: Aptitude Health; AstraZeneca/Daiichi Sankyo; Exact Sciences; G1 Therapeutics; Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi.
Dr. Lisa Carey, a breast cancer specialist from the University of North Carolina at Chapel Hill, looks at the latest data in metastatic breast cancer presented at the 2021 American Society of Clinical Oncology Annual Meeting.
First, Dr. Carey reviews an updated analysis from the PALOMA-3 trial of the CDK4/6 inhibitor palbociclib plus fulvestrant in women with HR+/HER2- advanced disease. This report showed that the observed survival benefit with the combination is maintained out to 6 years.
Next, she describes another updated survival analysis, this time from the MONALEESA-3 trial, which assessed fulvestrant plus another CDK4/6 inhibitor, ribociclib, in postmenopausal women with HR+/HER2- advanced disease. Again, the combination was associated with a survival benefit of almost 5 years, as well as a delay in subsequent chemotherapy.
Dr. Carey then reviews the Chinese sysucc-002 trial of endocrine therapy or chemotherapy added to trastuzumab in HR+/HER2+ disease. With noninferior outcomes and lower toxicity, trastuzumab plus endocrine therapy could become the preferred option and allow women to avoid chemotherapy.
She next turns to a subanalysis of the ASCENT trial, which examined sacituzumab govitecan in previously treated triple-negative disease. Even in the second-line metastatic setting, the drug showed a survival benefit.
Dr. Carey concludes by discussing a study that gathered patients’ views on treatment-related adverse effects, finding that over 90% would be willing to discuss alternative dosing options to improve their quality of life.
--
Jacobs Preyer Distinguished Professor, Breast Cancer Research, University of North Carolina at Chapel Hill; Deputy Director, Clinical Sciences, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Lisa A. Carey, MD, has disclosed the following relevant financial relationships:
Institution received research funding from: AbbVie; Immunomedics; NanoString Technologies; Novartis; Seattle Genetics; Syndax; Veracyte
Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme.
Other uncompensated relationships through institution: Aptitude Health; AstraZeneca/Daiichi Sankyo; Exact Sciences; G1 Therapeutics; Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi.
Dr. Lisa Carey, a breast cancer specialist from the University of North Carolina at Chapel Hill, looks at the latest data in metastatic breast cancer presented at the 2021 American Society of Clinical Oncology Annual Meeting.
First, Dr. Carey reviews an updated analysis from the PALOMA-3 trial of the CDK4/6 inhibitor palbociclib plus fulvestrant in women with HR+/HER2- advanced disease. This report showed that the observed survival benefit with the combination is maintained out to 6 years.
Next, she describes another updated survival analysis, this time from the MONALEESA-3 trial, which assessed fulvestrant plus another CDK4/6 inhibitor, ribociclib, in postmenopausal women with HR+/HER2- advanced disease. Again, the combination was associated with a survival benefit of almost 5 years, as well as a delay in subsequent chemotherapy.
Dr. Carey then reviews the Chinese sysucc-002 trial of endocrine therapy or chemotherapy added to trastuzumab in HR+/HER2+ disease. With noninferior outcomes and lower toxicity, trastuzumab plus endocrine therapy could become the preferred option and allow women to avoid chemotherapy.
She next turns to a subanalysis of the ASCENT trial, which examined sacituzumab govitecan in previously treated triple-negative disease. Even in the second-line metastatic setting, the drug showed a survival benefit.
Dr. Carey concludes by discussing a study that gathered patients’ views on treatment-related adverse effects, finding that over 90% would be willing to discuss alternative dosing options to improve their quality of life.
--
Jacobs Preyer Distinguished Professor, Breast Cancer Research, University of North Carolina at Chapel Hill; Deputy Director, Clinical Sciences, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Lisa A. Carey, MD, has disclosed the following relevant financial relationships:
Institution received research funding from: AbbVie; Immunomedics; NanoString Technologies; Novartis; Seattle Genetics; Syndax; Veracyte
Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme.
Other uncompensated relationships through institution: Aptitude Health; AstraZeneca/Daiichi Sankyo; Exact Sciences; G1 Therapeutics; Genentech/Roche; GlaxoSmithKline; Novartis; Sanofi.
